medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2014, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (1)

Results of the treatment of child Acute Lymphoid Leukemia in Cuba

González OA, Menéndez VA, Machín GS, Svarch E, Campo DM, Fernández NR, Martínez CL, Pavón MV, Márquez HE, Pérez GS, Lam DRM, Arencibia NA, Jaime FJC, Macías AC, Amor VAM, Marsán SV

Language: Spanish
References: 31
Page: 36-46
PDF size: 95.13 Kb.


ABSTRACT

Introduction: Acute lymphoid leukaemia (ALL) is the most frequent malignant disease in childhood and the first one to be treated with a common protocol in Cuba. Different protocols have been used and at present there are 10 health centers in Cuba treating children with ALL.
Objective: To present the results achieved in the treatment of ALL from 2002 to 2008 with protocol ALLIC (Acute Lymphoblastic Leukemia Intercontinental).
Methods: 166 children under 18 years old at the beginning of the disease were treated. Different criteria were used to make prognostic groups which included age and leukocyte counts in the peripheral smear at diagnosis, DNA molecular rearrangements and response to therapy.
Results: Event free survival (EFS) after 4 years for the whole group was 69 % and overall survival (SV) was 78 %. EFS in the different prognostic groups were 85 % for standard risk patients, 77 % for the intermediate risk group and 59 % for high risk children. Percentage of initial remission in our patients was lower than the one obtained for the whole group. The majority of early deaths occurred at the beginning of the protocol application. Bone marrow relapses were the more frequent ones. Central nervous system, testicular or combined relapses were lower than 5 %. DNA rearrangements for bcr/abl or MLL/AF4 were signs of very bad prognosis.
Conclusions: These results, even when susceptible to be better, show an adequate level considering that they were achieved in a developing country.


REFERENCES

  1. Svarch E, González A, Lagarde M, Vergara B. Tratamiento de la LLA del niño. Bol Med Hosp Infantil México. 1980:37:707-14.

  2. Svarch E, Vergara B, Lagarde M, González A, Quintero I, Fernández O. et al. Tratamiento de la leucemia linfoblástica aguda (LLA) Sangre. 1980;25:411-6.

  3. Svarch E, Vergara B, González A, Lagarde M. Tratamiento de la leucemia linfocítica aguda. Rev Cubana Invest Biomed. 1982;1(1):38-44.

  4. González A, Vergara B, Svarch E. Resultados preliminares del tratamiento de la leucemia aguda linfoblástica (LAL) en Cuba con los protocolos 3-LLA-82 y 1-LLA-84 Rev Cubana Hemat Inmunol Hemoter. 1986;21:263-8.

  5. Svarch E, González A, Vergara B, Campo M, Méndez J, Fernández O, et al. Tratamiento de la leucemia linfoide aguda (LLA) en el niño. Sangre. 1993;38(1):251-7.

  6. González A, Pérez A, Svarch E. Valor de la clasificación en grupos pronósticos de la leucemia aguda linfoblástica de la infancia Rev Cubana Hemat Inmunol Hemoter. 1989;5(3):436-40.

  7. Bennett JC, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Oct;103(4):620-5.

  8. Pui CH, Relling MV, Pharm D, Downing JR. Acute lymphoblastic leukemia 2004 Apr;350(15):1535-48.

  9. Campana D, Coustan-Smith F. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002 Mar;15(1):1-19.

  10. Marsán-Suárez V, del Valle-Pérez L, Socarrás-Ferrer B, Sánchez-Segura M, Macías-Abraham C, Mazorra-Herrrera Z, et al Validación del ultramicrométodo inmunocitoquímico (UMICIQ) para el inmunofenotipaje de la leucemia linfoide pediátrica Rev Cubana Hematol Inmunol Hemoter. 2012 Abr-Jun;29(3):74-78.

  11. Jakovljovic G, Nakic M, Rogosic S, Kardum-Skclic I, Zadro R, Kroslic B. Pre-Bcell acute lymphoblastic leukemia with bulk extramedullary disease and Chromosome 22 (EWSR1) rearrangement masquerading as Ewing sarcoma. Pediatr Blood Cancer. 2010 Apr;54(4):606-9.

  12. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med. 1998 Aug;339(9):605-15.

  13. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukaemia. J Clin Oncol. 2005 Sep;23(26):6306-15.

  14. Pui CH. Childhood leukemias. N Engl J Med. 1995 Jun;332(24):1618-30.

  15. Assumpção JG, Ganazza MA, de Araújo M, Silva AS, Scrideli CA, Brandalise SR, etal. Detection of clonal Immunoglobulin and T-cell receptor gene rearrangement in childhood acute lymphoblastic leukemia using a low-cost PCR strategy. Pediatr Blood Cancer. 2010 Dec;55(7):1278-86. doi:10.1002/pbc.22709.

  16. Ritter J, Creutzig U, Reier A, Riehm H, Schellong G. Childhood leukemias: Cooperative Berlin-Frankfurt-Munster trials in Federal Republic of Germany. J Cancer Res Clin Oncol. 1990;116(1):100-3.

  17. ALLIC. ALLIC-BFM 2002 Protocol progress reports 23-30, 20th Annual Meeting of the International BFM Study Group May 8th to 10th 2009, Bergamo, Italy.

  18. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomized children. Childhood ALL Collaborative Group. Lancet. 1996 Jun;347(9018):1783-8.

  19. Verdiman HJ, Kamps WA, van en Berg H, van den Berg E, Bokkrink JPA, Bruin CA, et al. Dexamethasone based therapy for childhood acute lymphoblastic leukaemia results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009 Oct;10(10):957-66. doi:10.1016/S1470-2045(09)70228-1.

  20. Biondi A, Baruchel A, Hunger S, Masera G, Schmiiegelow K, Schrappe M, et al. The eleventh international childhood acute lymphoblastic leukemia workshop Ponte di Legno Italy 6-7 may 2009. Leukemia. 2009 Dec;23(12):2318-24.

  21. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promisingoutcome for newly diagnosed BCR-ABLpositive acute lymphoblastic leukemia. A phase II study by the Japan Acute Leukemia Study Group. J Clin Oncol. 2006 Jan;24(3):460-6.

  22. Sazawal S, Bakhshi S, Raina J, Swaroop Csayen R. Detection and clinical relevance of bcr-abl fusion gene in T cell lineage ALL .Report of four cases: J Pediatr Hematol Oncol. 2009 Nov;31(11):850-2.

  23. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia. Update of prognostic factors Curr Opin Pediatr. 2009:21(1) 1-8.

  24. Pui CH. T cell lymphoblastic leukemia NOTCHing the way towards a better treatment outcome Cancer Cell 2009 Feb;15(2) 85-7. doi:10.1016/j.ccr.2009.01.007.

  25. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection . Leukemia. 2005 Jan;19(1):49-56.

  26. Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol. 2008 Nov;143(4):481-9.

  27. Burnett AK, Eden OB. The treatment of acute leukaemia. Lancet. 1997 Jan;349(9047):270-5.

  28. Fichr T, Schrauder A, Cazzaniga C, Panzer-Grümayer P, van der Velden V, Fischer S, et al. On behalf of the International BFM Study Group (I-BFM-SG) Minimal residual disease directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008 Apr;22(4):771-82.

  29. Attarbaschi A, Marin G, Panzer-Grúmayer P, Rutgers S, Steiner M, Königen M, et al. Minimal residual disease values discriminate between low and high risk in children with B cell precursor acute lymphoblastic leukemia and intrachromosomal amplification +of chromosome 21: The Austrian and German acute Lymphoblastic leukemia Berlin-Frankfurt-Münster (ALL-BFM) trial. J Clin Oncol. 2008 Jun;26(18):3046-50.

  30. Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, et al. Minimal residual disease based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese childhood cancer and leukemia study group. Pediatr Blood Cancer. 2010 Dec;55(7):1287-95.

  31. Basso G, Veltroni M, Valsecchi MG, Henze G, Ludwig WD, Schumich A, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of minimal residual disease on day 15 bone marrow. J Clin Oncol. 2009:27(31):5168-74.




2020     |     www.medigraphic.com